Literature DB >> 18381376

Predictors of slow flow during primary percutaneous coronary intervention: an intravascular ultrasound-virtual histology study.

J H Bae1, T-G Kwon, D-W Hyun, C S Rihal, A Lerman.   

Abstract

OBJECTIVES: Slow flow phenomenon is a serious complication of percutaneous coronary intervention (PCI) and is associated with a poor prognosis. We sought to evaluate the characteristics of lesions predisposing to the slow/no-reflow phenomenon during primary PCI in patients with acute myocardial infarction.
METHODS: The study subjects consisted of 57 consecutive patients (mean age 58.5 (SD 14.5) years, 45 males) who underwent primary PCI for acute myocardial infarction and intravascular ultrasound-virtual histology (IVUS-VH) examination. Slow flow was defined as <or= thrombolysis in myocardial infarction grade 2 after PCI.
RESULTS: Slow flow developed in 12 patients (eight males). Patients with slow flow were likely to be older (67.5 (13.8) years vs 56.2 (13.9) years, p = 0.015), had more cardiogenic shock (16.7% vs 2.2%, p = 0.046), larger fibrofatty volume over the entire lesion length (36.7 (25.5) mm(3) vs 18.0 (18.6) mm(3), p = 0.006), higher remodelling index (1.10 (0.17) vs 0.99 (0.16), p = 0.043), larger plaque area (16.2 (5.4) mm(2) vs 12.5 (4.9) mm(2), p = 0.025), fibrous area (8.0 (3.3) mm(2) vs 5.4 (3.0) mm(2), p = 0.014) and fibrofatty area (2.7 (2.2) mm(2) vs 1.3 (1.6) mm(2), p = 0.016) at the minimal lumen site than those without slow flow (37 males). Multivariate analysis revealed that the fibrofatty volume over the entire lesion length was the only independent factor (beta = 0.359, 95% confidence interval 0.002 to 0.012, p = 0.006) for slow flow during primary PCI.
CONCLUSIONS: This study suggests that slow flow may be dependent on the tissue characterisation (fibrofatty volume) of the underlying lesion at the time of the primary PCI for acute myocardial infarction.

Entities:  

Mesh:

Year:  2008        PMID: 18381376     DOI: 10.1136/hrt.2007.135822

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Intravascular ultrasound appearance of scattered necrotic core as an index for deterioration of coronary flow during intervention in acute coronary syndrome.

Authors:  Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Takao Matsubara; Yoshihide Uno; Toshihiko Yasuda; Kenji Miwa; Honin Kanaya; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2011-08-12       Impact factor: 2.037

2.  Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.

Authors:  Woong Gil Choi; Megha Prasad; Ryan Lennon; Rajiv Gulati; Abhiram Prasad; Lilach O Lerman; Amir Lerman
Journal:  Coron Artery Dis       Date:  2018-03       Impact factor: 1.439

3.  Predictors of Impaired Reperfusion after Percutaneous Coronary Intervention in Patients with In-Hospital Acute Stent Thrombosis: A Retrospective Analyses of 5 Years of Data.

Authors:  Burak Açar; Orhan Maden; Kevser Gülcihan Balci; Sefa Ünal; Mustafa Mücahit Balci; Esra İpek Gücük; Meryem Kara; Hatice Selcuk; Mehmet Timur Selcuk
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

4.  Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Yundai Chen; Changhua Wang; Xinchun Yang; Lefeng Wang; Zhijun Sun; Hongbin Liu; Lian Chen
Journal:  Heart Vessels       Date:  2011-04-28       Impact factor: 2.037

5.  Impact of thin-cap fibroatheroma on predicting deteriorated coronary flow during interventional procedures in acute as well as stable coronary syndromes: insights from optical coherence tomography analysis.

Authors:  Tadatsugu Gamou; Kenji Sakata; Takao Matsubara; Toshihiko Yasuda; Kenji Miwa; Masaru Inoue; Honin Kanaya; Tetsuo Konno; Kenshi Hayashi; Masaaki Kawashiri; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2014-07-19       Impact factor: 2.037

6.  Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention.

Authors:  Hua Zhou; Xiao-Yan He; Shao-Wei Zhuang; Juan Wang; Yan Lai; Wei-Gang Qi; Yi-An Yao; Xue-Bo Liu
Journal:  World J Emerg Med       Date:  2014

7.  Intravascular Ultrasound-based Imaging Modalities for Tissue Characterisation.

Authors:  Andrejs Erglis; Sanda Jegere; Inga Narbute
Journal:  Interv Cardiol       Date:  2014-08

8.  Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures.

Authors:  Francesco Prati; Giulio Guagliumi; Gary S Mintz; Marco Costa; Evelyn Regar; Takashi Akasaka; Peter Barlis; Guillermo J Tearney; Ik-Kyung Jang; Elosia Arbustini; Hiram G Bezerra; Yukio Ozaki; Nico Bruining; Darius Dudek; Maria Radu; Andrejs Erglis; Pascale Motreff; Fernando Alfonso; Kostas Toutouzas; Nieves Gonzalo; Corrado Tamburino; Tom Adriaenssens; Fausto Pinto; Patrick W J Serruys; Carlo Di Mario
Journal:  Eur Heart J       Date:  2012-05-31       Impact factor: 29.983

9.  Fibro-Fatty Component is Important for the Long-Term Clinical Events in Patients Who Have Undergone Primary Percutaneous Coronary Intervention.

Authors:  Wan Ho Kim; Hyun Woong Park; Ki Hong Kim; In Girl Song; Dong Ju Yang; Chung Seop Lee; Young Hoon Seo; Taek Geun Kwon; Jang-Ho Bae
Journal:  Korean Circ J       Date:  2012-01-31       Impact factor: 3.243

10.  Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis.

Authors:  Young Joon Hong; Myung Ho Jeong; Yun Ha Choi; Jum Suk Ko; Min Goo Lee; Won Yu Kang; Shin Eun Lee; Soo Hyun Kim; Keun Ho Park; Doo Sun Sim; Nam Sik Yoon; Hyun Ju Youn; Kye Hun Kim; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Eur Heart J       Date:  2009-02-19       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.